TRT Nation vs Maximus: Clinical Selection Criteria

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

TRT Nation and Maximus are two prominent telehealth platforms offering testosterone replacement therapy, but they differ significantly in eligibility criteria, biomarker interpretation, and clinical oversight. TRT Nation emphasizes rapid assessment and lower barriers to entry, while Maximus positions itself as a more medically rigorous platform with stricter baseline requirements. Understanding these differences helps patients and providers align expectations around who qualifies for TRT and under what clinical conditions.

The choice between TRT Nation and Maximus—or pursuing TRT through traditional in-person medicine—hinges on individual biomarkers, symptom profiles, and baseline health status. Beyond comparing these platforms, a precision-wellness perspective recognizes that genetic predispositions in hormone-regulatory pathways may provide context for personalized TRT dosing and response patterns. PlexusDx's Precision Peptide Genetic Test examines variants in pathways relevant to metabolic and hormonal regulation, which can support more informed conversations with qualified providers evaluating TRT eligibility.

TRT Nation Platform: Selection Model and Clinical Requirements

TRT Nation uses a streamlined evaluation model prioritizing accessibility and speed. Applicants complete an online questionnaire covering symptoms (fatigue, mood, sexual function, muscle loss) and undergo basic lab testing for total testosterone, free testosterone, and hematocrit. The platform typically accepts candidates with testosterone levels below 400 ng/dL, though borderline cases may be reviewed individually by licensed providers.

TRT Nation's approach appeals to men seeking convenience and faster pathways to treatment initiation. The platform operates in multiple states with varying regulatory frameworks, meaning eligibility criteria may shift by jurisdiction. Clinical oversight includes monthly check-ins and periodic lab monitoring, though the frequency and depth of biomarker assessment is less intensive than in traditional urology or endocrinology settings. Men with uncomplicated hypogonadism and stable baseline health often find TRT Nation's model sufficient for their needs.

Maximus: Rigorous Clinical Framework and Biomarker Integration

Maximus adopts a more conservative clinical stance, requiring comprehensive baseline laboratory assessment before TRT initiation. Candidates must demonstrate total testosterone below 300 ng/dL or free testosterone below 9 pg/mL, and Maximus providers conduct detailed cardiovascular, prostate, and metabolic screening. The platform emphasizes documentation of symptoms concurrent with low biomarkers—reducing the risk of treating asymptomatic hypogonadism or age-related decline alone.

Maximus's intake process includes discussion of contraindications: untreated sleep apnea, active polycythemia, severe benign prostatic hyperplasia, or uncontrolled hypertension may disqualify candidates or require specialist clearance. Follow-up frequency is typically more structured, with quarterly labs and provider telehealth visits. This approach aligns more closely with endocrinology society guidelines, appealing to men who value medical thoroughness and have complex medical histories or multiple comorbidities.

Biomarker-Guided Comparison: TRT Nation vs Maximus Framework

Both platforms use testosterone level thresholds, but interpretation and supplementary testing differ. The table below outlines key clinical decision factors that distinguish their frameworks and can help patients understand which model aligns with their medical profile and preferences.

Clinical Factor	TRT Nation Approach	Maximus Approach	Clinical Relevance
Total testosterone threshold	Below 400 ng/dL typically eligible	Below 300 ng/dL standard requirement	Maximus uses stricter cutoff; TRT Nation accepts broader range
Free testosterone measurement	Often skipped if total is low	Consistently measured and interpreted	Free T is more physiologically relevant than total T alone
Cardiovascular screening	Basic history; limited additional workup	EKG, lipid panel, BP monitoring standard	Maximus reduces CV risk via comprehensive baseline
Prostate-specific antigen (PSA)	Not always checked at baseline	Baseline PSA recommended for all candidates	PSA aids early detection; Maximus prioritizes prostate safety
Hematocrit and polycythemia monitoring	Checked; modest follow-up frequency	Frequent monitoring; stricter intervention thresholds	TRT raises hematocrit; Maximus applies tighter safety margins
Symptom–biomarker concordance	Symptoms alone can support eligibility	Symptoms must align with lab findings	Maximus avoids treating asymptomatic low-T due to age alone

Clinical Considerations Beyond Platform Eligibility

Testosterone replacement is not a single-protocol therapy. Individual baseline metabolic status—insulin sensitivity, body composition, lipid profile—influences how men respond to TRT and tolerate dose escalation. A man with uncontrolled type 2 diabetes may require more vigilant glucose and lipid monitoring during TRT than a metabolically healthy candidate, regardless of which platform delivers treatment. Both TRT Nation and Maximus require providers to assess these contexts, though depth of assessment varies.

Genetic predispositions in metabolic and hormonal regulation pathways can inform provider conversations about expected response patterns and personalized dosing strategies. Variants in genes involved in androgen receptor signaling, estrogen metabolism, and insulin sensitivity may correlate with differential TRT responsiveness, though current evidence remains emerging. PlexusDx's Precision Peptide Genetic Test evaluates key hormone-regulatory variants—including metabolic and androgen-relevant markers—that may help clinicians contextualize individual TRT trajectories when paired with clinical judgment and ongoing biomarker monitoring.

Safety, Contraindications, and Provider Oversight Models

Both TRT Nation and Maximus require qualified medical providers (typically physicians or nurse practitioners licensed in the patient's state), but regulatory standards and clinical governance differ. TRT Nation operates in a competitive telehealth environment prioritizing patient access; Maximus enforces stricter clinical guardrails aligned with endocrinology society recommendations. Neither model is inherently 'safer'—outcomes depend on individual provider competence, patient adherence to monitoring, and baseline health status.

Men with contraindications—active malignancy, untreated obstructive sleep apnea, severe lower urinary tract symptoms, or estrogen-dependent breast cancer—should not pursue TRT regardless of platform. Both services should screen for these conditions, though Maximus's structured approach may catch nuanced contraindications more consistently. Long-term safety requires ongoing communication between patient and provider: reporting new symptoms, maintaining consistent lab work, and adjusting dosing based on biomarker response and clinical outcomes.

How PlexusDx Supports a More Personalized Approach

Genetic variation in hormone-metabolic pathways—including androgen receptor signaling and estrogen aromatization—may influence how individual men respond to testosterone dosing and side-effect profiles. While TRT eligibility decisions rely primarily on biomarkers like total testosterone, free testosterone, and hematocrit, understanding an individual's genetic predispositions in these pathways can provide additional context for provider conversations about personalized dosing strategy and monitoring intensity.

PlexusDx's Precision Peptide Genetic Test examines key variants in hormone-regulatory and metabolic genes that may reveal predispositions relevant to TRT response and safety. This test does not predict exact testosterone response or guarantee optimal outcomes—genetic predisposition is one factor among many—but results can support a more nuanced conversation between patient and qualified healthcare provider about individualized TRT protocols, monitoring frequency, and potential side-effect susceptibility.

Whether pursuing TRT through TRT Nation, Maximus, or traditional in-person medicine, combining standard biomarker assessment with genetic insight creates a more complete picture of individual candidacy and expected trajectory. Discussing your genetic test results with a qualified provider helps contextualize why you may respond differently to TRT than population averages, enabling more precise dosing and proactive monitoring.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the main difference between TRT Nation and Maximus eligibility criteria?

TRT Nation typically accepts candidates with total testosterone below 400 ng/dL, while Maximus requires stricter thresholds (total T below 300 ng/dL or free T below 9 pg/mL) and mandates comprehensive cardiovascular, prostate, and metabolic screening. Maximus emphasizes symptom–biomarker concordance; TRT Nation accepts faster pathways to treatme...

Does TRT Nation or Maximus offer genetic testing to guide TRT selection?

Neither TRT Nation nor Maximus currently includes genetic testing in their standard eligibility frameworks. PlexusDx's Precision Peptide Genetic Test examines hormone-metabolic variants that may contextualize individual TRT response and inform provider conversations about personalized dosing—complementing biomarker-based selection.

How often do TRT Nation and Maximus require follow-up monitoring?

TRT Nation typically schedules monthly check-ins with periodic lab testing; Maximus enforces more frequent quarterly labs and structured telehealth visits. Maximus's model aligns more closely with endocrinology society guidelines for safety monitoring, particularly hematocrit, PSA, and cardiovascular markers.

Can PlexusDx help me decide between TRT Nation and Maximus?

PlexusDx does not directly offer TRT. However, our Precision Peptide Genetic Test can provide insights into hormone-regulatory variants that inform conversations with your qualified healthcare provider about personalized TRT strategy—whether you pursue treatment through TRT Nation, Maximus, or traditional medicine.

What role do biomarkers play in TRT eligibility?

Both platforms use testosterone levels (total and free), hematocrit, and symptom assessment. Maximus adds PSA, cardiovascular screening, and metabolic profiling. Genetic predispositions in hormone pathways may refine provider interpretation of biomarkers and support discussion of personalized dosing protocols.

Are there contraindications that disqualify me from both TRT Nation and Maximus?

Yes. Active cancer, untreated sleep apnea, severe lower urinary tract symptoms, and estrogen-dependent breast cancer are contraindications across both platforms. Maximus's rigorous screening may identify nuanced contraindications more consistently than TRT Nation's streamlined intake.

TRT Nation vs Maximus: Biomarker-Driven Selection Frameworks